Peripheral Blood Stem Cell TransplantationHematopoietic Stem Cell TransplantationTransplantation, HomologousGraft vs Host DiseaseTransplantation ConditioningHematologic NeoplasmsTransplantation, AutologousStem Cell TransplantationHematopoietic Stem Cell MobilizationTransplantation ChimeraGranulocyte Colony-Stimulating FactorGraft SurvivalBusulfanBone Marrow TransplantationTissue DonorsAntigens, CD34VidarabineTreatment OutcomeLeukapheresisRecurrenceMyeloablative AgonistsGraft vs Leukemia EffectImmunosuppressive AgentsStem CellsLeukemiaMelphalanCombined Modality TherapyHistocompatibility TestingRemission InductionHematopoietic Stem CellsMultiple MyelomaHistocompatibilityRetrospective StudiesCyclophosphamideSurvival AnalysisCord Blood Stem Cell TransplantationWhole-Body IrradiationBlood Component RemovalAntineoplastic Combined Chemotherapy ProtocolsLeukemia, Myeloid, AcuteDisease-Free SurvivalPrecursor Cell Lymphoblastic Leukemia-LymphomaLeukemia, Myelogenous, Chronic, BCR-ABL PositiveSalvage TherapyLymphoma, Non-HodgkinSurvival RateGraft vs Tumor EffectEtoposideCytomegalovirus InfectionsLymphocyte TransfusionChronic DiseaseMyelodysplastic SyndromesAntineoplastic Agents, AlkylatingHLA AntigensLymphocyte DepletionTime FactorsTransplantation, IsogeneicInfectionLiver TransplantationT-LymphocytesCytarabineThiotepaAnemia, AplasticHodgkin DiseaseSiblingsNeoplasm, ResidualHematopoiesisPOEMS SyndromeTransplantation ImmunologyVincristineFollow-Up StudiesCyclosporineHematologic DiseasesMesenchymal Stem Cell TransplantationAntilymphocyte SerumAmyloidosisImmunosuppressionCarmustineLymphomaFatal OutcomeAcute DiseaseBlood CellsPrognosisCell TransplantationOpportunistic InfectionsKidney TransplantationIfosfamideAntineoplastic AgentsBone MarrowChimerismEmbryonic Stem CellsMinor Histocompatibility AntigensHepatic Veno-Occlusive DiseaseImmunophenotypingPlatelet CountNeoplasmsProspective StudiesVirus ActivationBlood DonorsFeasibility Studies